{"entity":{"id":"modex-therapeutics","kind":"company","name":"ModeX Therapeutics","aka":["ModeX Therapeutics, An OPKO Health Company"],"tldr":"ModeX Therapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the tetraspecific T-cell engagers MDX2001 and MDX2003 in biliary tract cancer, cervical cancer, colorectal cancer and endometrial cancer.","summary":"ModeX Therapeutics develops multispecific antibodies and nanoparticle vaccines for cancer and infectious disease. Its oncology pipeline includes MDX2001 (cMET x Trop2 x CD3 x CD28) for solid tumours and MDX2003 (CD19 x CD20 x CD3 x CD28) for B-cell leukaemia and lymphoma, both tetraspecific T-cell engagers. It is a wholly owned subsidiary of OPKO Health. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06239194 (phase 1/2, Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors) and NCT07249905 (phase 1/2, Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.modextherapeutics.com"},{"label":"ClinicalTrials.gov: trials led by ModeX Therapeutics","url":"https://clinicaltrials.gov/search?lead=ModeX%20Therapeutics%2C%20An%20OPKO%20Health%20Company"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cholangiocarcinoma","cervical","colorectal","endometrial","esophageal","gastric","non-hodgkin-lymphoma","waldenstrom","dlbcl","follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06239194","nct07249905"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Weston, Massachusetts","country":"US","companyType":"biotech","website":"https://www.modextherapeutics.com","founded":2013,"stage":"acquired","investors":[],"funding":[]},"route":"/companies/modex-therapeutics/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"trial":[{"id":"nct06239194","kind":"trial","name":"Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors","route":"/trials/nct06239194/"},{"id":"nct07249905","kind":"trial","name":"Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma","route":"/trials/nct07249905/"}]}}